Your browser doesn't support javascript.
loading
Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort.
Teepen, Jop C; Kremer, Leontien C; van der Heiden-van der Loo, Margriet; Tissing, Wim J; van der Pal, Helena J; van den Heuvel-Eibrink, Marry M; Loonen, Jacqueline J; Louwerens, Marloes; Versluys, Birgitta; van Dulmen-den Broeder, Eline; Visser, Otto; Maduro, John H; van Leeuwen, Flora E; Ronckers, Cecile M.
Afiliación
  • Teepen JC; Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands. J.C.Teepen@prinsesmaximacentrum.nl.
  • Kremer LC; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. J.C.Teepen@prinsesmaximacentrum.nl.
  • van der Heiden-van der Loo M; Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
  • Tissing WJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
  • van der Pal HJ; Dutch Childhood Oncology Group, Utrecht, The Netherlands.
  • van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
  • Loonen JJ; Department of Pediatric Oncology/Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Louwerens M; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
  • Versluys B; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
  • van Dulmen-den Broeder E; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, The Netherlands.
  • Visser O; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Maduro JH; Department of Internal Medicine/Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Leeuwen FE; Department of Pediatric Oncology and Hematology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
  • Ronckers CM; Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Cancer Causes Control ; 30(9): 909-922, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31300947
ABSTRACT

PURPOSE:

Childhood cancer survivors are at increased risk of developing subsequent malignant neoplasms (SMNs). We compared survival and clinical characteristics of survivors with SMNs (sarcoma, breast cancer, or melanoma) and a population-based sample of similar first malignant neoplasm (FMN) patients.

METHODS:

We assembled three case series of solid SMNs observed in a cohort of 5-year Dutch childhood cancer survivors diagnosed 1963-2001 and followed until 2014 sarcoma (n = 45), female breast cancer (n = 41), and melanoma (n = 17). Each SMN patient was sex-, age-, and calendar year-matched to 10 FMN patients in the population-based Netherlands Cancer Registry. We compared clinical and histopathological characteristics by Fisher's exact tests and survival by multivariable Cox regression and competing risk regression analyses.

RESULTS:

Among sarcoma-SMN patients, overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.23-2.87] and sarcoma-specific mortality (HR 1.91, 95% CI 1.16-3.13) were significantly worse compared to sarcoma-FMN patients (foremost for soft-tissue sarcoma), with 15-year survival rates of 30.8% and 61.6%, respectively. Overall survival did not significantly differ for breast-SMN versus breast-FMN patients (HR 1.14, 95% CI 0.54-2.37), nor for melanoma-SMN versus melanoma-FMN patients (HR 0.71, 95% CI 0.10-5.00). No significant differences in tumor characteristics were observed between breast-SMN and breast-FMN patients. Breast-SMN patients were treated more often with mastectomy without radiotherapy/chemotherapy compared to breast-FMN patients (17.1% vs. 5.6%).

CONCLUSIONS:

Survival of sarcoma-SMN patients is worse than sarcoma-FMN patients. Although survival and tumor characteristics appear similar for breast-SMN and breast-FMN patients, treatment differs; breast-SMN patients less often receive breast-conserving therapy. Larger studies are necessary to substantiate these exploratory findings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sarcoma / Neoplasias Cutáneas / Neoplasias de la Mama / Neoplasias Primarias Secundarias / Supervivientes de Cáncer / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Cancer Causes Control Asunto de la revista: EPIDEMIOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sarcoma / Neoplasias Cutáneas / Neoplasias de la Mama / Neoplasias Primarias Secundarias / Supervivientes de Cáncer / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Cancer Causes Control Asunto de la revista: EPIDEMIOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos